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SUMMARY AND CONCLUSIONS
ïhe nuclear  enzyme DNA topoisomerase l l  ( topo l l )  is  a target  of  many
ant icancer  agents,  inc luding several  ef fect ive chemotherapeut ic  drugs which are
used in the c l in ic ,  e.g.  the anthracycl ines and etoposide.  In  Chapter  1 an
overv iew is  g iven of  the funct ion of  topo l l ,  the c lass ic  topo l l  drugs,  and thei r
in teract ion.  Centra l  in  th is  in teract ion is  the format ion of  a c leavable complex
compr is ing DNA and topo l l ,  which is  s tabi l ized by the drug.  Stabi l izat ion of  the
complex resul ts  in  pers is tent  DNA strand-breaks and th is  wi l l  in i t ia te a process
that  leads to cel l -death.  Therefore these drugs have been designated topo l l
po isons.  Their  act iv i ty  is  d i rect ly  re lated to the amount  of  c leavable complex that
is  formed and thus to the topo l l  level  and act iv i ty .  Recent ly  a new c lass of  topo
l l  d i rected drugs has been ident i f ied.  These agents are d i rect  inh ib i tors of  topo l l
cata ly t ic  act iv i ty  and do not  s tabi l ize the c leavable complex.  In  contrast  to  the
topo l l  po isons,  topo l l  cata ly t ic  inh ib i tors are most  ef fect ive when the topo l l
levels  are low.  Therefore,  these new drugs may be of  va lue when topo l l  speci f ic
tumor drug-res is tance (atMDR = a l tered topo l l  mul t idrug res is tance)  occurs.
The c l in ica l  s tudies d iscussed in th is  thesis  had the purpose to explore some
possib i l i t ies of  innovat ive use oÍ  the c lass ic  topo l l  drug etoposide,  to  invest igate
the oraf  adminis t rat ion of  the etoposide prodrug etoposíde phosphate and to
study the tox ic i ty  and pharmacokinet ics of  the topo l l  cata ly t ic  inh ib i tor
fost r iec in.
Etoposide is  a topo l l  po ison wi th proven ef f icacy in  several  mal ignant  d iseases,
especia l ly  when i t  is  used in combinat ion wi th other  chemotherapeut ic  agents.
The combinat ion of  etoposide wi th c isp lat in  shows synergy in  v i t ro and is  one of
the most  ef Íect ive ant icancer  drug combinat ions for  the t reatment  of  germ cel l
tumors and smal l  ce l l  lung cancer.  Chapter  2 concerns the appl icat ion of  th is
drug combinat ion in  advanced ovar ian cancer.  This  c l in ica l  phase l l  s tudy was
designed to invest igate drug-ef f icacy in  a specia l  group of  pat ients:  those in
whom a smal l  tumor res idue (< 2 cm) remains af ter  induct ion chemotherapy and
second- look laparotomy.  Cisplat in  was adminis tered in t raper i toneal ly  because
th is  of fers the h ighest  drug level  at  the per i toneal  tumor s i tes,  and etoposide
was g iven int ravenously.  Of  the 36 pat ients,  640/o had a c l in ica l  response and in
seven pat ients a pathological  complete response was f  ound at  surg ical
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evaluat ion.  The median progression- f ree surv iva l  of  a l l  pat ients was 1 1 months.
This indicates that ,  despi te the h igh response rate,  most  pat ients developed a
re lapse wi th in a re lat ive shor t  in terval ,  inc luding a considerable number
int raper i toneal  re lapses.  The lat ter  ind icates an insuÍ f ic ient  local  ef fect  of  th is
t reatment .  Resul ts  might  be improved by the use of  h igher  c isp lat in  doses and
more restr ic ted select ion oÍ  pat ients (e.9.  microscopic les ions only) .
ln  Chapter  3 the publ ished studies on pro longed low-dose etoposide mono-
therapy are rev iewed.  In v i t ro s tudies demonstrated the rapid revers ib i l i ty  of
etoposide induced DNA-les ions once the drug is  removed and therefore prov ide a
rat ionale for  pro longed dosing.  Fur thermore,  the ef fect  of  etoposide is  ce l l -cyc le
dependent .  In  randomized c l in ica l  s tudies i t  was demonstrated that  mul t ip le-days
dosing is  super ior  to  s ingle-dose schedules.  Subsequent ly ,  the ef f icacy oÍ
pro longed (  > 1O days)  low-dose etoposide t reatment  was invest igated in  a large
number of  phase l l  s tudies.  This is  f  ac i l i ta ted by the possib i l i ty  of  ora l
adminis t rat ion.  The resul ts  of  these t r ia ls  show that  th is  is  an ef fect ive
t reatment  in  smal l -ce l l  lung cancer and mal ignant  lymphoma. The act iv i ty  is
promis ing in  pat ients wi th breast  or  ovar ian cancer and e i ther  d isease ref ractory
to standard t reatment  or  a re lapse shor t ly  thereaf ter .  However,  important
quest ions remain to be answered.  There is  a lack of  comparat ive t r ia ls  to
convent ional  etoposide dose-schedules and i t  was not  def in i te ly  proven that  the
tox ic i ty-prof i le  of  pro longed low-dose etoposide compares Íavorably.
In Chapter  4 the act iv i ty  of  pro longed low-dose ora l  etoposide was invest igated
in  17  pa t i en t s  w i t h  advanced  ep i t he l i a l  ova r i an  cance r  and  p rog ress i ve  d i sease
du r i ng ,  o r  re laps ing  a f t e r ,  p r i o r  chemothe rapy .  Because  re l i ab le  t umor  measu re -
men ts  a re  d i f f i cu l t  i n  such  pa t i en t s ,  t he  CA-125  se rum leve l  was  used  as
disease parameter .  The course of  th is  tumor marker  dur ing ora l  etoposide
treatment  was analyzed and compared to i ts  course dur ing the preceding t ime
interval .  We found a marked overal l  decrease of  the rate of  CA-125 progression
du r i ng  e topos ide  t rea tmen t :  t he  mean  CA-125  doub l i ng - t ime  i nc reased  more
than ten- fo ld.  Because d isease stabi l izat ion is  a val id  goal  in  such pat ients and
because oÍ  the advantages of  ora l  adminis t rat ion,  ora l  etoposide can be
considered a valuable t reatment  opt ion.
The errat ic  b ioavai labi l i ty  is  an important  drawback of  ora l  etoposide.  Etoposide
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af ter  in t ravenous adminis t rat ion.  ln  Chapter  5 we compared the p lasma-
pharmacokinet ics of  etoposide af ter  ora l  etoposide and ora l  etoposide phosphate
In 1 5 pat ients wi th sol id  tumors.  The median AUCi, r  (area under the
concentrat ion versus t ime curve f rom zero to in f in i ty)  oÍ  etoposide was 77.7
mg / l . h  a f t e r  e topos ide  phospha te  (95% C l  61 .3 -100 .5 )  and  62 .O  mg / t . h  a f t e r
ora l  etoposide (95o/o Cl  52.2-76.91 . There was a smal l  but  s tat is t ica l ly
s igni f icant  d i f ference in favor  of  etoposide phosphate:  median 9.9 mg/ l .h  (95%
Cl  0 .1 -32 .8 ) .  Howeve r ,  t h i s  d i f Í e rence  rep resen ts  on l y  1O7o  i nc rease  o Í  t he
bioavai labi l i ty  and there remained a large in ter-pat ient  var iabi l i ty  in  the p lasma
levels of  etoposide (coef f ic ient  of  var iat ion 42.3o/o l  .  Thus,  ora l  etoposide
phosphate does not  of fer  a pharmacological ly  re levant  benef  i t  over  ora l
etoooside.
To invest igate the gastro intest inal  handl ing of  the prodrug etoposide
phosphate,  we per formed the study descr ibed in Chapter  6.  In  th is  s tudy i t  was
analyzed in v i t ro whether  prodrug convers ion to etoposide occurs in  human
gastr ic  ju ice or  in  b i le .  Prodrug convers ion to etoposide in  gastr ic  ju ice was
negl ig ib le.  The percentage of  prodrug converted to etoposide in  b i le  at  pH 8
af ter  t  h  was 78 + 187o (mean + SD) for  a O. ' l  mg/ml  prodrug solut ion and 36
+ 260/o Íor  0.5 mg/ml .  At  pH 7 convers ion was less,  but  af ter  t  h  22o/o of
p rod rug  was  conve r ted  when  i ncuba ted  w i th  b i l e  a t  0 .1  mg /m l  and  10% a t  0 .5
mg/ml .  l t  is  probable that  convers ion of  prodrug to etoposide was caused by
alkal ine phosphatase present  in  the b i le .  This  s tudy shows that  var iable
convers ion to etoposide can be expected wi th in the gastro intest inal  lumen.  This
may af fect  the supposed pharmacological  advantage of  the prodrug etoposide
phosphate af ter  ora l  adminis t rat ion.
In Chapter  7 the precl in ica l  l i terature on the topo l l  cata ly t ic  inh ib i tor  fost r iec in is
rev iewed.  l t  was found that  several  tumor cel l  l ines wi th decreased topo l l  levels
and drug-res is tance to c lass ic  topo l l  po isons reta ined thei r  sensi t iv i ty  to
fos t r i ec in .  I n  GLCo  human  sma l l  ce l l  l ung  cance r  ce l l  l i nes  an  i nve rse  re la t i on  was
found between topo l l  levels  and fost r iec in cytotox ic i ty .  Recent ly  possib le other
mechanisms of  act ion of  Íost r iec in were repor ted in  addi t ion to the ef Íects on
topo l l ,  in  par t icu lar  inh ib i t ion of  the nuclear  prote in phosphatases PP1 and PP2A
and h is tone phosphatases.  Fur ther  invest igat ion is  needed to determine the
re lat ive contr ibut ion of  the d i f ferent  mechanisms of  act ion to the ant i tumor
act iv i tv  of  fost r iec in.
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In Chapters 8 and 9 a c l in ica l  phase ls tudy of  fost r iec in is  descr ibed.  Fostr iec in
was adminis tered as 1-hour in t ravenous infus ions for  5 days in  2O sol id  tumor
pat ients.  The dose was escalated to 20 mglm2lday.  The major  tox ic i t ies of
fost r iec in were e levated b lood l iver  t ransaminases and a decrease of  renal
funct ion.  Dose- l imi t ing tox ic i ty ,  o f  the l iver ,  was encountered in one of  two
pat ients aï  20 mg/m2iday.  However,  the maximum to lerated dose was not
reached,  because the fost r iec in supply was stopped.  The lat ter  was due to the
fact  that  the suppl ier ,  the US Nat ional  Cancer Inst i tu te,  detected an
unacceptable percentage impur i t ies (8%) in  the c l in ica l  batches and was unable
to  so l ve  t h i s  p rob lem.
The l iver  and renal  tox ic i t ies peaked af ter  the f i rs t  1  to 2 out  of  5 doses per
course and d id not  increase wi th cont inued adminis t rat ion.  There was onlv a
l imi ted increase of  the l iver  tox ic i ty  wi th increasing fost r iec in doses and no
relat ion between the decrease in renal  funct ion and the dose- level  at  doses >4
mglm2lday.  These observat ions might  be expla ined by saturat ion or  deplet ion of
t he  reduced - fo la te  ca r r i e r  mechan i sm,  wh i ch  i s  respons ib le  f o r  t he  ce l l u i a r
uptake of  Íost r iec in.  However,  th is  explanat ion requi res demonstrat ion of  the
p resence  o f  t h i s  ca r r i e r  i n  no rma l  human  l i ve r  and  k idney  ce l l s .  Ano the r  ques t i on
ra ised by the observed course of  the tox ic i t ies is  whether  the possib le ant i tumor
ef fects of  fost r iec in are s imi lar ly  l imi ted at  the present  dose-schedule.
The renal  tox ic i ty  of  fost r iec in was fur ther  analyzed wi th accurate studies on
rena l  hemodynamics  i n  e igh t  pa t i en t s .  A  med ian  dec rease  o Í  360 /o  i n  GFR was
observed dur ing fost r iec in adminis t rat ion.  A 1 SO-fo ld increase in ur inary Br-
m ic rog lobu l i n  concen t ra t i on  du r i ng  f  os t r i ec in  admin i s t ra t i on  i nd i ca tes  t ha t
fos t r i ec in  caused  a  rena l  t ubu la r  abno rma l i t y .  The  obse rved  rena l  hemodynamic
changes were compat ib le wi th renal  tubular  damage.  Because the renal  tox ic i ty
recove red  immed ia te l y  a f t e r  d rug  admin i s t ra t i on  and  w i th in  1 -2  weeks ,  i t  i s  l i ke l y
tha t  f os t r i ec in  i nduces  p r imar i l y  f unc t i ona l  a l t e ra t i ons  and  on l y  l im i t ed
morpho log i ca l  damage .  The  exac t  mechan i sm o f  t he  rena l  t ox i c i t y  needs  Íu r the r
i nves t i ga t i on .
The pharmacokinet ic  s tudies revealed that  fost r iec in has a shor t  p lasma hal Í -
l i f e :  t he  med ian  te rm ina l  ha l f - l i f e  i n  t he  two -compar tmen t  mode l  was  1 .5  h .
About  150Á oÍ  the drug is  renal ly  excreted unal tered.  A metabol i te  was detected
which was most  probably dephosphory lated fost r iec in.  This metabol i te  is  of
par t icu lar  in terest ,  because the presence of  the phosphate group is .  at  least  in
v i t r o ,  essen t i a l  f o r  t he  an t i t umor  ac t i v i t y  o f  f os t r i ec in .
We also invest igated whether  the drug p lasma levels achieved in v ivo could
be
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be re lated to a s igni f  icant  in  v i t ro ant i tumor ef Íect .  Therefore cel ls  oÍ  a
teniposide (VM-26) res is tant  ce l l  l ine,  GLC4/VM2." ,  were incubated wi th pat ient
p lasma samples obta ined dur ing fost r iec in in fus ion.  GLC4/VM2."  was selected
because the teniposide res is tance was due to a reduced topo l l  level .  This  cel l
l ine can be considered an in  v i t ro model  of  the perceived target  populat ion for
the c l in ica l  use of  fost r iec in.  The resul ts  suggested that  Íur ther  fost r iec in dose-
escalat ion wi th at  least  50% to 1OO% is requi red before a c l in ica l  ant i tumor
ef fect  can be expected.  The present  data on the tox ic i t ies of  fost r iec in do not
preclude th is  approach.  However,  several  observat ions in  th is  s tudy indicate that
the fost r iec in dose-schedule should be reconsidered.  Because of  the shor t
p lasma hal f - l i fe ,  longer in fus ion might  be preferred wi th regard to ef f icacy.  On
the other  hand,  the re lat ion between the dose-schedule and the tox ic i t ies and
the oossib le ro le of  the reduced fo late carr ier  a lso need to be e luc idated.  In  v iew
of  the present  c l in ica l  data Íur ther  invest igat ion oÍ  fost r iec in is  just i f ied and no
f inal  conclus ions about  the c l in ica l  potent ia l  o f  th is  drug are possib le at  the
present .
The studies descr ibed in th is  thesis  explored some of  the possib i l i t ies for
improvement  of  ant icancer  drug therapy a imed at  topo l l .  Other  opt ions are
discussed in chapter  1.  In  the nearby future,  resul ts  of  c l in ica l  s tudies wi th topo
l l  cata ly t ic  inh ib i tors wi l l  def ine the possib le c l in ica l  ro le of  these agents.  Fur ther
c l in ica l  development  of  rat ional  drug combinat ions inc luding topo l l  d i rected
d rugs ,  i n  pa r t i cu la r  comb ina t i ons  w i th  t opo  I i nh ib i t o r s ,  i s  wa r ran ted .  The
relat ion between topo l l  level  and/or  act iv i ty  of  tumors in  pat ients and the
sensi t iv i ty  to  par t icu lar  drugs is  an important  f ie ld for  c l in ica l  research.  Other
st rategies foreseen in the future may inc lude manipulat ion of  the drug target  at
the topo l l -gene level .
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